×

연수막전이가 있는 비소세포폐암 환자의 치료 성적과 표적치료제의 효과를 보고함.

항암화학요법을 시행 받는 한국 노인 암환자에서 노인포괄평가의 결과 및 유용성을 보고함.

더 이상 항암화학요법이 불가능한 진행 암환자에서 여명을 예측할 수 있는 예후 예측 지표를 보고함.

흡연력이 있는 진행 암환자에서 화학적 대처(chemical coping)의 위험인자를 보고함.

Yennurajalingam S, Kim YJ, Zhang Y, Park J, Arthur J, Chisholm GB, Williams JL, Bruera E. Factors associated with patient-reported subjective well-being among advanced lung or non-colonic gastrointestinal cancer patients. Palliat Support Care. Palliat Support Care. 2018 Feb;16(1):23-31.

Choi Y, Yun MS, Lim SH, Lee J, Ahn JH, Kim YJ, Park KH, Park YS, Lim HY, An H, Suh DC, Kim YH. Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study. Cancer Res Treat. 2018 Jan;50(1):175-182.

Kim T, Song C, Han JH, Kim IA, Kim YJ, Kim SH, Kim JH, Kim CY. Epidemiology of Intracranial Metastases in Korea: A National Cohort Investigation. Cancer Res Treat. 2018 Jan;50(1):164-174.

Shin DW, Suh SY, Kim SH, Park J, Yoon SJ, Kim YJ, Kang B, Kwon JH, Park Y, Park K, Hui D, Kim HJ, Himchak S, Lee SS, Ahn HY. Is spirituality related to survival in advanced cancer inpatients in Korea? Palliat Support Care. 2017 Dec 21. [Epub ahead of print]

Kim TM, Lee KW, Oh DY, Lee JS, Im SA, Kim DW, Han SW, Kim YJ, Kim TY, Kim JH, Han H, Kim WH, Bang YJ. Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Cancer Res Treat. 2017 Aug 29. [Epub ahead of print]

Kim SH, Kim MJ, Kim YJ, Chang H, Kim JW, Lee JO, Lee KW, Kim JH, Bang SM, Lee JS. Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy. Medicine (Baltimore). 2017 Oct;96(42):e8176.

Lim SH, Yoh KA, Lee JS, Ahn MJ, Kim YJ, Kim SH, Zhang J, Patel D, Swallow E, Kageleiry A, Galebach P, Lee D, Stein K, Degun R, Park K. Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea. Asia Pac J Clin Oncol. 2017 Oct;13(5):e239-e245.

Lee DW, Im SA, Kim YJ, Yang Y, Rhee J, Na II, Lee KH, Kim TY, Han SW, Choi IS, Oh DY, Kim JH, Kim TY, Bang YJ. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy. Cancer Res Treat. 2017 Jul;49(3):807-815.

Suh KJ, Sung JH, Kim JW, Han SH, Lee HS, Min A, Kang MH, Kim JE, Kim JW, Kim SH, Lee JO, Kim YJ, Lee KW, Kim JH, Bang SM, Im SA, Lee JS. EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. Oncotarget. 2017 Jul 12;8(38):63901-63910.

Lim YJ, Lee SW, Choi N, Kwon J, Eom KY, Kang E, Kim EK, Kim SW, Kim JH, Kim YJ, Kim SH, Park SY, Kim JS, Kim IA. Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice. Breast Cancer Res Treat. 2017 Jun;163(3):555-563.

Wee CW, Kim E, Kim N, Kim IA, Kim TM, Kim YJ, Park CK, Kim JW, Kim CY, Choi SH, Kim JH, Park SH, Choe G, Lee ST, Chang JH, Kim SH, Suh CO, Kim IH. Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. Radiother Oncol. 2017 Apr;123(1):106-111.

Cha Y, Kim YJ, Lee SH, Kim TM, Choi SH, Kim DW, Park CK, Kim IH, Kim JH, Kim E, Choi B, Kim CY, Kim IA, Heo DS. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. Cancer Res Treat. 2017 Jan;49(1):129-140.

Chang H, Oh J, Zhang X, Kim YJ, Lee JH, Lee CT, Chung JH, Lee JS. EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy. Onco Targets Ther. 2016 Aug;9:5153-5162.

Kim YJ, Dev R, Reddy A, Hui D, Tanco K, Park M, Liu D, Williams J, Bruera E. Association Between Tobacco Use, Symptom Expression, and Alcohol and Illicit Drug Use in Advanced Cancer Patients. J Pain Symptom Manage. 2016 Apr;51(4):762-8.

Kim YJ, Munsell MF, Park JC, Meyer LA, Sun CC, Brown AJ, Bodurka DC, Williams JL, Chase DM, Bruera E, Ramondetta LM. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol. 2015 Dec;139(3):553-8.

Lee SJ, Kim TM, Kim YJ, Jang KT, Lee HJ, Lee SN, Ahn MS, Hwang IG, Lee S, Lee MH, Lee J. Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). Oncologist. 2015 Nov;20(11):1312-9.

Cho KM, Kim YJ, Kim SH, Kim JW, Lee JO, Han JH, Lee KW, Kim JH, Kim CY, Bang SM, Kim IA, Kim JS, Lee JS. Salvage Treatment with Intracerebrospinal Fluid Thiotepa in Patients with Leptomeningeal Metastasis After Failure of Methotrexate-based Treatment. Anticancer Res. 2015 Oct;35(10):5631-8.

Park S, Keam B, Kim SH, Kim KH, Kim YJ, Kim JS, Kim TM, Lee SH, Kim DW, Lee JS, Heo DS. Pemetrexed Singlet versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-Small Cell Lung Cancer Patients with EGFR Mutations. Cancer Res Treat. 2015 Oct;47(4):630-7.

Kim YH, Kim T, Joo JD, Han JH, Kim YJ, Kim IA, Yun CH, Kim CY. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. Cancer. 2015 Sep 1;121(17):2926-32.

Kim JW, Kim SH, Kim YJ, Lee KW, Kim KI, Lee JS, Kim CH, Kim JH; Korean Cancer Study Group Geriatric Oncology Working Party. A Novel Geriatric Screening Tool in Older Patients with Cancer: The Korean Cancer Study Group Geriatric Score (KG)-7. PLoS One. 2015 Sep 24;10(9):e0138304.

Kim YJ, Hui D, Zhang Y, Park JC, Chisholm G, Williams J, Bruera E. Differences in Performance Status Assessment Among Palliative Care Specialists, Nurses, and Medical Oncologists. J Pain Symptom Manage. 2015 Jun;49(6):1050-1058.

Sim SH, Kim YJ, Kim SH, Keam B, Kim TM, Lee SH, Kim DW, Heo DS, Lee JS. Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2015 Jun;141(6):1073-81.

Delgado-Guay MO, Kim YJ, Shin SH, Chisholm G, Williams J, Allo J, Bruera E. Avoidable and Unavoidable Visits to the Emergency Department Among Patients With Advanced Cancer Receiving Outpatient Palliative Care. J Pain Symptom Manage. 2015 Mar;49(3):497-504.

Hui D, Kim YJ, Park JC, Zhang Y, Strasser F, Cherny N, Kaasa S, Davis MP, Bruera E. Integration of oncology and palliative care: a systematic review. Oncologist. 2015 Jan;20(1):77-83.

Kim YJ, Kim SH, Kim JW, Lee JO, Kim JH, Bang SM, Lee JS, Lee KW. Gastric cancer with initial bone metastasis: a distinct group of diseases with poor prognosis. Eur J Cancer. 2014 Nov;50(16):2810-21.

Lee JL, Park SH, Koh SJ, Lee SH, Kim YJ, Choi YJ, Lee J, Lim HY. Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program. Cancer Chemother Pharmacol. 2014 Nov;74(5):1005-13.

Kim YJ, Kim SJ, Lee JK, Choi WS, Park JH, Kim HJ, Sim SH, Lee KW, Lee SH, Kim JH, Kim DW, Lee JS, Bang YJ, Heo DS. Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis. J Cancer Res Clin Oncol. 2014 Sep;140(9):1567-74.

Lee KW, Kim YJ, Lee KH, Han SW, Kim TY, Oh DY, Im SA, Kim TY, Bang YJ, Choi IS, Kim JH. Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. Cancer Chemother Pharmacol. 2014 Sep;74(3):447-55.

Han JJ, Kim YJ, Kim JW, Chang H, Lee JO, Lee KW, Jeong CW, Kim JH, Hong SK, Bang SM, Byun SS, Lee SE, Lee JS. Salvage treatment with low-dose weekly paclitaxel in elderly or poor performance status patients with metastatic urothelial carcinoma. Tumori. 2014 Jul-Aug;100(4):439-45.

Bae SH, Park MJ, Lee MM, Kim TM, Lee SH, Cho SY, Kim YH, Kim YJ, Park CK, Kim CY. Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. J Korean Med Sci. 2014 Jul;29(7):980-4.

Lee DW, Chang H, Kim YJ, Kim KM, Lee HJ, Lee JS. Sorafenib-Induced Tumor Response in a Patient With Metastatic Epithelioid Angiomyolipoma. J Clin Oncol. 2014 Apr 10;32(11):e42-5.

Kim YJ, Kim MJ, Cho YJ, Park JS, Kim JW, Chang H, Lee JO, Lee KW, Kim JH, Yoon HI, Bang SM, Lee JH, Lee CT, Lee JS. Who should be admitted to the intensive care unit? The outcome of intensive care unit admission in stage IIIB-IV lung cancer patients. Med Oncol 2014 Mar;31(3):847.

Kim JW, Kim YJ, Lee KW, Chang H, Lee JO, Kim KI, Bang SM, Lee JS, Kim CH, Kim JH. The early discontinuation of palliative chemotherapy in older patients with cancer. Support Care Cancer 2014 Mar;22(3):773-81.

Kim M, Chang H, Yang HC, Kim YJ, Lee CT, Lee JH, Jheon S, Kim K, Chung JH, Lee JS. Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer. World J Surg Oncol. 2014 Feb 12;12:37.

Chang JH, Kim CY, Choi BS, Kim YJ, Kim JS, Kim IA. Pseudoprogression and pseudoresponse in the management of high-grade glioma : optimal decision timing according to the response assessment of the neuro-oncology working group. J Korean Neurosurg Soc. 2014 Jan;55(1):5-11.